IBRX

IBRX

Immunitybio Inc

Rev 3768xtop 1%10Y
Hold

ImmunityBio, Inc. develops next-generation immunotherapies to activate the immune system against cancer and infectious diseases. Its primary revenue source is the FDA-approved immunotherapy Anktiva for treating BCG-unresponsive non-muscle invasive bladder cancer.

βš•οΈ Healthcare NASDAQ Listed 2015 $ USD
$1,000 invested 10 years ago β†’$1,047today

Score Overview

1 Year
Score
Net Growth-182.40%
Net TrendShrank
Net Income Consistencyβ€”
Rev Growth46.35%
Rev TrendGrew
Revenue Consistencyβ€”
5 Years
Score4.2
Net Growth-186.16%
Net Trend40%
Net Income Consistencyβ€”
Rev Growth177x
Rev Trend80%
Revenue Consistencyβ€”
10 Years
Score
Net Growth-6x
Net Trend50%
Net Income Consistency
Rev Growth3768x
Rev Trend80%
Revenue Consistency
All Time
Score
Net Growth-318.94%
Net Trend55%
Net Income Consistency
Rev Growth702x
Rev Trend73%
Revenue Consistency

See the full market ranking β†’

Immunitybio Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 605K to $ 113M and net income went from -$ 221M to -$ 351M. Revenue increased in 4 of those 5 years; net income in 2.

Across Immunitybio Inc's full reported history, from 2015 to 2025, revenue grew from $ 236K to $ 113M and net income went from -$ 236M to -$ 351M. Revenue increased in 73% of the years measured; net income in 55%.

Immunitybio Inc currently holds a 5-year HDB Score of 4.2 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 7.74β€”
1 Year2025-08-12
$ 2.47213.36%
5 Years2021-08-12
$ 11.40-32.11%
10 Years2016-08-12
$ 7.394.74%
All Time2015-07-28
$ 34.64-77.66%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 165M-$ 992M$ 357M
2025$ 113M-$ 351M$ 242M
2024$ 14M-$ 413M$ 149M
2023$ 622K-$ 583M$ 266M
2022$ 240K-$ 416M$ 107M
2021$ 934K-$ 346M$ 317M
2020$ 605K-$ 221M$ 96M
2019$ 43K-$ 65M$ 51M
2018$ 47K-$ 96M$ 74M
2017$ 45K-$ 96M$ 128M
2016$ 44K-$ 120M$ 198M
IPO2015$ 236K-$ 236M$ 294M

Explore beyond IBRX

You're looking at Immunitybio Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies